Adulterated drugs represent a serious and acute global health problem within a largely unregulated pharmaceutical industry. It is estimated that 10–30% of drug sales are counterfeit in parts of Africa, Asia, and Latin America. PharmaChk’s primary objective is to develop and commercialize a device to screen for substandard medicines, thereby improving adverse health outcomes. PharmaChk is a user-friendly, cost-effective, high-throughput device capable of quantitatively measuring active ingredient concentration and drug release rates to quickly and accurately screen for spurious medicines. Existing detection technologies are bulky, qualitative, error-prone, and do not record time-based measurements of drug release kinetics, disregarding important information concerning therapeutic drug levels. PharmaChk addresses these shortcomings through affordable, fluorescence-based dissolution testing, which allows for highly specific and quantitative time-course measurements of drug release. PharmaChk is in the final stages of development, and an interdisciplinary team of Boston University graduate students is currently preparing for product commercialization in 2013. United States Pharmacopeia has expressed interest in procuring the final product and is our initial client. A utility patent will be filed early next year, and a for-profit entity will be established to license PharmaChk to interested parties. It is estimated that market research along with identification of manufacturers will be completed by the end of this year with staff hiring being targeted for the middle of next year. If successful, PharmaChk will offer an affordable, effective tool for local health authorities to better safeguard the efficacy of their pharmacopeia and provide better access to quality medicines. PharmaChk is currently participating in Stage 2 of the E-Team program.